Amma Owusu-Ansah

Amma Owusu-Ansah

Auto-generated profile, based on publicly available information

Amma Owusu-Ansah

Sickle Cell Anemia Center, University Hospitals Rainbow Babies & Children’s Hospital, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in The American Journal of Medicine
Verified
Journal Article
Closed access
GTGeoffrey Tsaras
Geoffrey Tsaras
AOAmma Owusu-Ansah
Amma Owusu-Ansah
FBFreda Owusua Boateng
Freda Owusua Boateng
YAYaw Amoateng-Adjepong
Yaw Amoateng-Adjepong

1 January 2016 in Translational Research
Verified
Journal Article
Closed access
AOAmma Owusu-Ansah
Amma Owusu-Ansah
CIChibueze A. Ihunnah
Chibueze A. Ihunnah
AWAisha L. Walker
Aisha L. Walker
SOSolomon F. Ofori-Acquah
Solomon F. Ofori-Acquah

7 April 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
SGSamit Ghosh
Samit Ghosh
CIChibueze A. Ihunnah
Chibueze A. Ihunnah
RHRimi Hazra
Rimi Hazra
AWAisha L. Walker
Aisha L. Walker
JHJason Hansen
Jason Hansen
SOSolomon F. Ofori-Acquah
Solomon F. Ofori-Acquah
The prevention of organ damage and early death in young adults is a major clinical concern in sickle cell disease (SCD). However, mechanisms that control adult progression of SCD during the transition from adolescence are poorly defined with no cognate prophylaxis. Here, we demonstrate in a longitudinal cohort of homozygous SCD (SS) mice a link between intravascular hemolysis, vascular inflammation, lung injury, and early death. Prophylactic Nrf2 activation in young SS mice stabilized intravascular hemolysis, reversed vascular inflammation, and attenuated lung edema in adulthood. Enhanced Nrf2 activation in endothelial cells in vitro concurred with the dramatic effect on vascular inflammation in the mice. BM chimeric SS mice lacking Nrf2 expression in nonhematopoietic tissues were created to dissect the role of nonerythroid Nrf2 in SCD progression. The SS chimeras developed severe intravascular hemolysis despite having erythroid Nrf2. In addition, they developed premature vascular inflammation and pulmonary edema and died younger than donor littermates with intact nonhematopoietic Nrf2. Our results reveal a dominant protective role for nonhematopoietic Nrf2 against tissue damage in both erythroid and nonerythroid tissues in SCD. Furthermore, we show that prophylactic augmentation of Nrf2-coordinated cytoprotection effectively impedes onset of the severe adult phenotype of SCD in mice.

4 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AKAmma Benneh-Akwasi Kuma
Amma Benneh-Akwasi Kuma
AOAmma Twumwa Owusu-Ansah
Amma Twumwa Owusu-Ansah
MAMary Akua Ampomah
Mary Akua Ampomah
FSFredericka Sey
Fredericka Sey
EOEdeghonghon Olayemi
Edeghonghon Olayemi
SOSolomon Fiifi Ofori-Acquah
Solomon Fiifi Ofori-Acquah
Individuals with sickle cell disease particularly with the homozygous (SS) genotype historically have relatively low blood pressure. Nonetheless, they develop vasculopathy-associated organ dysfunction and the risk of organ dysfunction increases at blood pressures that are normal in the general population. This phenomenon is termed relative systemic hypertension (RSH) with a systolic blood pressure range of 120–139 mmHg, and diastolic blood pressure range of 70–89 mmHg. The significance of RSH lies in its association with renal insufficiency, pulmonary hypertension, stroke and propensity to progress to systemic hypertension. We conducted a retrospective chart review of 1,000 adults with sickle cell disease at the Ghana Institute of Clinical Genetics, to determine the prevalence of RSH in sickle cell disease in Ghana and associated complications. We found a high prevalence of RSH and hypertension with a relatively low frequency of renal insufficiency. Pulse pressure, a predictor of mortality, was higher in males of all ages. We anticipate that providing an estimate of the burden of RSH will heighten its recognition and clinical management among health care providers.

8 June 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
REReem Elagooz
Reem Elagooz
ADAnita R Dhara
Anita R Dhara
RGRose M. Gott
Rose M. Gott
SASarah E. Adams
Sarah E. Adams
RWRachael A. White
Rachael A. White
MGMerlin Nithya Gnanapragasam
Merlin Nithya Gnanapragasam
The fetal-to-adult hemoglobin switching at about the time of birth involves a shift in expression from γ-globin to β-globin in erythroid cells. Effective re-expression of fetal γ-globin can ameliorate sickle cell anemia and β-thalassemia. Despite the physiological and clinical relevance of this switch, its posttranscriptional regulation is poorly understood. Here, we identify Pumilo 1 (PUM1), an RNA-binding protein with no previously reported functions in erythropoiesis, as a direct posttranscriptional regulator of β-globin switching. PUM1, whose expression is regulated by the erythroid master transcription factor erythroid Krüppel-like factor (EKLF/KLF1), peaks during erythroid differentiation, binds γ-globin messenger RNA (mRNA), and reduces γ-globin (HBG1) mRNA stability and translational efficiency, which culminates in reduced γ-globin protein levels. Knockdown of PUM1 leads to a robust increase in fetal hemoglobin (∼22% HbF) without affecting β-globin levels in human erythroid cells. Importantly, targeting PUM1 does not limit the progression of erythropoiesis, which provides a potentially safe and effective treatment strategy for sickle cell anemia and β-thalassemia. In support of this idea, we report elevated levels of HbF in the absence of anemia in an individual with a novel heterozygous PUM1 mutation in the RNA-binding domain (p.(His1090Profs∗16); c.3267_3270delTCAC), which suggests that PUM1-mediated posttranscriptional regulation is a critical player during human hemoglobin switching.

15 December 2014 in Frontiers of Medicine
Verified
Journal Article
Closed access
PDF file
AOAmma Owusu-Ansah
Amma Owusu-Ansah
SCSung Hee Choi
Sung Hee Choi
APAgne Petrosiute
Agne Petrosiute
JLJohn J. Letterio
John J. Letterio
AHAlex Yee-Chen Huang
Alex Yee-Chen Huang